Company Overview
Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 25 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and lifeenhancing products ranging from small molecules to complex, genetically engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG, a globally renowned CDMO and provider of innovative proprietary technologies in the fields of monoclonal antibodies, protein, viral, and cell therapies to the global biotech industry at large, Minapharm has established an integrated business model making it to date the only gene-to-market biopharmaceutical company in the region.
Minapharm’s expression of SDG 3 (Good health and Wellbeing) is both clear and powerful. Biosimilars, which can reduce treatment costs by up to 70% compared to reference biologics, have the potential to unlock access to life-changing therapies to millions who are currently underserved. Through its biosimilars portfolio—targeting oncology, autoimmune diseases, and other high-burden conditions—Minapharm plays a critical role in improving health outcomes across Africa and the Middle East, reducing dependency on imports, lowering healthcare system costs, and increasing therapeutic coverage in line with public health priorities.In addition, this investment directly supports our focus SDGs - notably UN SDG 8 (Decent Work and Economic Growth). Minapharm is advancing Egypt’s position as a regional hub for biopharmaceutical innovation and technology, combining cutting-edge R&D with localized manufacturing to drive inclusive industrial growth. By enabling high-value job creation, supporting skills development, and strengthening regional self-sufficiency in healthcare, the company is contributing to long-term, knowledge-based economic resilience. The company also supports UN SDG 5 (Gender Equality), with women representing approximately one-third of the total workforce and 36% of management roles.